HC Wainwright & Co. Upgrades Prelude Therapeutics to Buy, Announces $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has upgraded Prelude Therapeutics (NASDAQ:PRLD) from Neutral to Buy, setting a price target of $5.
September 19, 2024 | 11:28 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Prelude Therapeutics has been upgraded by HC Wainwright & Co. from Neutral to Buy, with a new price target of $5. This upgrade could positively influence investor sentiment and potentially drive the stock price higher in the short term.
The upgrade from Neutral to Buy by a reputable analyst firm like HC Wainwright & Co. is likely to boost investor confidence in Prelude Therapeutics. The announcement of a $5 price target suggests potential upside, which could lead to increased buying activity and a rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100